Effect of anti‐ IL ‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: Evaluate anti‐interleukin‐1β ( IL ‐1β) antibody, canakinumab, in patients with type 2 diabetes and impaired glucose tolerance ( IGT ) in whom hyperglycaemia may trigger IL ‐1β‐associated inflammation leading to suppressed insulin secretion and β‐cell dysfunction. Methods: This 4‐week, parallel‐group study randomized 190 patients with type 2 diabetes 2 : 1, canakinumab versus placebo, into the following treatment arms: metformin monotherapy, metformin + sulfonylurea, metformin + sulfonylurea + thiazolidinedione or insulin ± metformin. IGT population (n = 54) was randomized 1 : 1, canakinumab versus placebo. Primary efficacy assessment was change from baseline in insulin secretion rate ( ISR ) relative to glucose 0–2 h. Results: Mean changes from baseline to week 4 in ISR relative to glucose at 0–2 h or other time points were not statistically significant for canakinumab versus placebo across groups. ISR (relative to glucose) at 0–0.5 h (first‐phase insulin secretion) numerically favoured canakinumab versus placebo in insulin‐treated patients {difference in mean change from baseline [point estimate ( PE )] 3.81 pmol/min/m 2 /mmol/l; p = 0.0525} and in the IGT group ( PE 3.92 pmol/min/m 2 /mmol/l; p = 0.1729). Mean change from baseline in fasting plasma glucose favoured canakinumab in the type 2 diabetes/metformin group and the IGT group; however, differences were not statistically significant. Mean change from baseline in peak insulin level and insulin AUC 0–4 h were statistically significantly higher in the canakinumab group in IGT patients. Canakinumab was well tolerated and consistent with known safety experience. Conclusions: The trend towards improving ISR relative to glucose 0–0.5 h in patients treated with insulin supports the hypothesis that insulin secretion can be improved by blocking IL ‐1β.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 1×
“The precise mechanism by which IL-1β is overproduced in type 2 diabetes remains to be fully elucidated, but recent research has demonstrated an amylin-induced activation of the NLRP3 inflammasome as a mechanism [14,15].”
BackgroundUse of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869 · cited 1×
“In 2009, canakinumab was approved by the US Food and Drug Administration and the European Medicines Agency for treating adults and children aged ≥4 years with cryopyrin-associated periodic syndromes (CAPS), producing durable remissions of these rare inherited inflammatory disorders [20].”
BackgroundRidker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Self-citationGerich, J. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.447 · Cited by 222 · cited 1×
“[2,3]), which would, in turn, suppress hepatic glucose production and the consequent diminished need for second-phase insulin release.”
BackgroundThe Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169 · cited 1×
“The stimulated inflammasome is known to activate pathogenic inflammatory cytokines, including IL-1β, by triggers including cholesterol crystals in atherosclerosis, or hyperglycaemia, ceramides and islet amyloid polypeptide in type 2 diabetes [27].”
BackgroundTreatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity
Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H., & Bartfai, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.004 · Cited by 160 · cited 1×
“Preclinical evidence suggests that blocking IL-1β reduces β-cell islet inflammation leading to increased insulin secretion, insulin sensitivity and reducing hyperglycaemia, which may slow or prevent the progression of type 2 diabetes [10,16,17].”
Background
Cited by
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Metadata
- Authors
- Rissanen, A., Howard, C. P., Botha, J., Thuren, T., & for the Global Investigators
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-07-19
- Volume
- 14
- Issue
- 12
- Pages
- 1088-1096
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2039664878
- Cited by
- 140
- References
- 8
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.